Troglitazone prevents hyperglycemia-induced but not glucosamine-induced insulin resistance

Diabetes

Volumn 47, Issue 3, 1998, Pages 395-400

  Miles, Philip D G ^a,c   Higo, Katsuya ^a   Romeo, Oreste M ^a   Lee, Moon Kyu ^b   Rafaat, Karim ^a   Olefsky, Jerrold M ^b  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c UCSD MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSAMINE; GLUCOSE; TROGLITAZONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; GLUCOSE HOMEOSTASIS; GLUCOSE UTILIZATION; HYPERGLYCEMIA; HYPERINSULINEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTRAVENOUS DRUG ADMINISTRATION; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; RAT;

ADMINISTRATION, ORAL; ANIMALS; BLOOD GLUCOSE; CHROMANS; COHORT STUDIES; GLUCOSAMINE; GLUCOSE CLAMP TECHNIQUE; HORMONE ANTAGONISTS; HYPOGLYCEMIC AGENTS; INFUSION PUMPS; INSULIN RESISTANCE; MALE; RATS; RATS, SPRAGUE-DAWLEY; SOMATOSTATIN; THIAZOLES; THIAZOLIDINEDIONES;

EID: 0031940449     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.47.3.395     Document Type: Article

References (35)

1. The Diabetes Control and Complications Trial Research Group; The effect of intensive treatment of diabeta on the development and progression of longterm complications In Insulin-dependent diabetes. N Engl J Med 329:977-986, 1993
2. Rossetti L, Giaccari A, DeFronzo RA; Glucose toxicity, Diabetes Care 13:610-630,1990
3. DeFronzo RA; Lilly Lecture 1987; the triumvirate: β-cell, muscle, liver; a collusion responsible for NIDDM Diabetes 37; 667-687,1988
4. Reaven GM, Sageman WS, Swenson RS; Development of insulin resistance In normal dogs following alloxan-induced insulin deficiency. Diabetologia 13:459-462,1977
5. Rossetti L. Smith D, Shulman GI, Papachristou D, DeFronzo RA: Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to Insulin In diabetic rats. J Clin Invest 79:1510-1515,1987
6. Lee TS, Saltman KA, Ohashi H, King GL; Activation of protein kinase C by glucose.Proc Natl Acad Sci USA 86:5141-5145,1989
7. Craven PA, Davidson CM, DeRobertis FR: Increase in diacylglycerol mass In isolated glomerull by glucose from de novo synthesis of glycerolipids. Diabetes 39:667-674,1990
8. Muller HK Kellerer M, Ermel B, Muhlhofer A, Obermaier-Kusscr B, Vogt B, HarIng HU; Prevention by protein kinase C inhibitors of glucose-induced insulinreceptor tyrosine kinase resistance In rat fat cells. Diabetes 40:1440-1448, 1991
9. Berti L, Mosthaf L, Kroder G, Kellerer M, Tippmer S, Mushack J, Seffer E, Seedorf K, Haring HU: Glucose-induced transiocation of protein kinase C isoforms in rat-1 fibroblasts Is paralleled by Inhibition of the Insulin receptor tyrosine kinase, J Biol Chem 269:3381-3386,1994
10. Marshall S, Bacote V, Traxinger RR: Discovery of a metabolic pathway mediating glucose-Induced desensitization of the glucose transport system. J Biol Chem 266:4706-4712,1991
11. Rossetti L, Hawkins M, Chen W, Gindi J, Barzllai N: In vivo glucosamine infusion induces Insulin resistance in normoglycemlc but not in hyperglycemie conscious rats. J Clin Invest 96:132-140,1995
12. Herbert L, McClain DA: Overexpression of glutamine:fructose-6-phosphate aminotransferase In skeletal muscle of transgenic mice results In Insulin resistance (Abstract). Diabetes 44:15,1995
13. Crook ED, Zhou J, Daniels M, Neidigh JL, McClain DA; Regulation of glycogen synthase by glucose, glucosamine, and glutamlne;fructose-ß-phosphate amidotransferase. Diabetes 44:314-320,1995
14. Iwamoti Y, Kuzuya T, Matsuda A, Awata T, Kumakura S, Inooka G, Shiraishi I: Effects of new oral antidiabetic agent CS-045 on glucose tolerance and insulin secretion in patients with NIDDM, Diabetes Care 14:1083-1086,1991
15. Suter SL, Nolan JJ, Wallace P, Gumbiner B, Olefsky JM: Metabolic effects of new oral hypoglycemie agent CS-045 in NIDDM subjects. Diabetes Care 15:193-203,1992
16. Nolan JJ, Ludvik B, Beerdsen P, Joyce M, Olefsky J: Improvement in glucose tolerance and insulin resistance In obese subjects treated with troglitazone. N Engl J Med 331:1188-1193,1994
17. Fujiwara T, Yoshioka S, Yoshioka T, Ushiyama I, Horikoshi H: Characterization of new oral antidiabetic agent CS-045: studies in KK and ob/ob mice and Zucker fatty rats. Diabetes 37:1549-1558,1988
18. Fujiwara T, Wada M, Fukuda K, Fukami M, Yorhioka S, Yoshioka T, Horikoshi H: Characterization of CS-045, a new oral antidiabetic agent. II. Effects on glycemic control and pancreatic islet structure In C57BL/KsJ-db/db mice. Metabolism 40:1213-1218,1991
19. Lee M-K, Miles PDG, Khoursheed M, Gao K-M, Moossa AR, Olefsky JM: Metabolic effects of troglitazone on fructose-Induced insulin resistance In the rat. Diabetes 43:1435-1430,1994
20. Revers RR, Fink R, Griffin J, Olefsky JM, Kolterman OG: Influence of hyperglycemia on insulin's in vivo effect in type II diubetes. J Clin Invest 73:664-672,1984
21. Desbuquois B, Aurbach GD: Use of polyethylene glycol to separate free and antibody-bound peptide hormone in radioimmunoassays, J Clin Endocrinol Metab 33:732-738,1971
22. Lipid research clinic. In Manual of Laboratory Operations, Revised Edition, Washington, DC, U.S. Department of Health and Human Services, 1982
23. Steele R: Influence of glucose loading and of Injected insulin on hepatic glucose output. Ann NY Acad Sci 82:420-430,1959
24. Baron AD, Brechtel G, Wallace P, Edelman SV: Rates and tissue sites of noninsulin and insulin-mediated glucose uptake In humans. Am J Physiol 255:E769-E774,1988
25. McClain DA, Crook ED: Hexosamines and Insulin resistance. Diabetes 45:1003-1009,1996
26. 6 myotubes. Biochim Biophys Acta 1201:113-117,1994
27. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkinson WO, Wilson TM, Kliewer SA; An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-ativated receptor -γ (PPARγ). J Biol chem 270:12953-12956,1995
28. Miyata KS, McCaw SE, Marcus SL, Rachubinski RA, Capone JP: The peroxisome proliferator-activated receptor interacts with the retinoid X receptor in vivo. Gene 148:327-330,1994
29. Gearing KL, Gottlicher M, Teboul M, Widmark E, Gustafsson JA: Interaction of the peroxisome-proliferator activated receptor and retinoid X receptor. Proc Natl Acad Sci USA 90:1440-1444,1993
30. Krey G, Mahfoudi A, Wahli W: Functional interactions of peroxisome proliferator-activated receptor, retinoid-X receptor, and Sp1 in the transcriptional regulation of the acyl-coenzyme-A oxidase promoter. Mol Endocrinol 9:219-231, 1995
31. Mukherjee R, Jow L, Noonan D, McDonnell DP: Human and rat peroxisome proliferator activated receptors (PPARs) demonstrate similar tissue distribution but different responsiveness to PPAR activators.J Steroid Biochem Mol Biol 51:157-166,1994
32. Braissnt O, Foufelle F, Scotto C, Dauca M, Wahli W: Differential expression of peroxisome proliferator-activated receptors (PPARs: tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat Endocrinology 137:354-366, 1996
33. Ciaraldi TP, Huber-Knudsen K, Hickman M, Oiefsky JM; Regulation of glucose transport in cultured muscle cells by novel hypoglycemic agents. Metabolism 44:976-981, 1995
34. Kellerer M, Kroder G, Tippmer S, Berti L, Kiehn R, Mosthaf L, Haring HU: Troglitazone prevents glucose-induced insulin resistance of insulin receptor in rat-1 fibroblasta Diabetes 43:447-453,1994
35. Baron AD, Zhu J-S, Zhu J-H, Weldon H, Maianu L, Garvey WT: Glucosamine induces insulin resistance in vivo by affecting GLUT 4 translocation in skeletal muscle. J clin Invest 96:2792-2801,1996